This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/kegg-drug/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/drugbank/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/national-drug-code-directory/
n14http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n24http://www.rxlist.com/cgi/generic/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01380/identifier/pubchem-compound/

Statements

Subject Item
n2:DB01380
rdf:type
n3:Drug
n3:description
Cortisone acetate is a steroid hormone that has both glucocoriticoid and mineral corticoid activities. Corticosteroids are used to provide relief for inflamed areas of the body. They lessen swelling, redness, itching, and allergic reactions. They are often used as part of the treatment for a number of different diseases, such as severe allergies or skin problems, asthma, or arthritis. Endogenous glucocorticoids and some synthetic corticoids have high affinity to the protein transcortin (also called CBG, corticosteroid-binding protein), whereas all of them bind albumin. Glucocorticoids also bind to the cytosolic glucocorticoid receptor.
n3:dosage
n22:271B43F9-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
owl:sameAs
n14:DB01380 n20:DB01380
dcterms:title
Cortisone acetate
adms:identifier
n6:D00973 n7:Cortisone_acetate n8:0009-0015-01 n9:C08173 n10:PA449130 n11:5543 n12:DB01380 n21:46508852 n23:5745
n3:mechanismOfAction
Cortisone acetate binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
n3:packager
n17:271B43E9-363D-11E5-9242-09173F13E4C5 n17:271B43EA-363D-11E5-9242-09173F13E4C5 n17:271B43E7-363D-11E5-9242-09173F13E4C5 n17:271B43E8-363D-11E5-9242-09173F13E4C5 n17:271B43ED-363D-11E5-9242-09173F13E4C5 n17:271B43EE-363D-11E5-9242-09173F13E4C5 n17:271B43EB-363D-11E5-9242-09173F13E4C5 n17:271B43EC-363D-11E5-9242-09173F13E4C5 n17:271B43EF-363D-11E5-9242-09173F13E4C5 n17:271B43F0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
n3:synonym
Cortisyl Cortone acetate
n3:toxicity
Side effects include inhibition of bone formation, suppression of calcium absorption, delayed wound healing and hyperglycemia.
n3:synthesisReference
Reichstein,T.; US. Patent 2,403,683; July 9, 1946. Gallagher,T.F.; US. Patent 2,447,325; August 17,1948; assigned to Research Corporation. Sarett, L.H.; U.S. Patent 2,541,104; February 13, 1951; assigned to Merck & Co., Inc.
foaf:page
n16:cortisone.html n24:cortisne.htm
n3:IUPAC-Name
n4:271B43FE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4404-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4403-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4400-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4401-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4402-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4414-363D-11E5-9242-09173F13E4C5 n4:271B43FC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4416-363D-11E5-9242-09173F13E4C5 n4:271B43FA-363D-11E5-9242-09173F13E4C5 n4:271B43FD-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B43FB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B440A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B440B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4405-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4406-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4408-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4407-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4409-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
50-04-4
n3:category
n3:containedIn
n18:271B43F3-363D-11E5-9242-09173F13E4C5 n18:271B43F4-363D-11E5-9242-09173F13E4C5 n18:271B43F1-363D-11E5-9242-09173F13E4C5 n18:271B43F2-363D-11E5-9242-09173F13E4C5 n18:271B43F7-363D-11E5-9242-09173F13E4C5 n18:271B43F8-363D-11E5-9242-09173F13E4C5 n18:271B43F5-363D-11E5-9242-09173F13E4C5 n18:271B43F6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4410-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4412-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4413-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4415-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B440F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B440E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4411-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B43FF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B440C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B440D-363D-11E5-9242-09173F13E4C5